Reduced CD37 expression in B cell subsets after stimulation and its clinical relevance in primary Sjögren's syndrome

IF 3.3 4区医学 Q3 IMMUNOLOGY

Immunology letters Pub Date : 2025-06-20 DOI:10.1016/j.imlet.2025.107054

Zhonghui Zhang , Jie Chen , Ziqi Xiong , Weijie Lin , Bohao Yang , Zhiwei Zong , Bing Shen , Hanxi Luo , Chen Liu

{"title":"Reduced CD37 expression in B cell subsets after stimulation and its clinical relevance in primary Sjögren's syndrome","authors":"Zhonghui Zhang , Jie Chen , Ziqi Xiong , Weijie Lin , Bohao Yang , Zhiwei Zong , Bing Shen , Hanxi Luo , Chen Liu","doi":"10.1016/j.imlet.2025.107054","DOIUrl":null,"url":null,"abstract":"<div><h3>Objective</h3><div>This study aims to analyse the expression of CD37 in different B cell subsets from human peripheral blood, exploring changes in CD37 expression in B cells of patients with primary Sjögren's syndrome (pSS) and assessing their clinical relevance.</div></div><div><h3>Methods</h3><div>A total of 32 pSS patients and age- and sex-matched healthy controls were included. Peripheral blood mononuclear cells (PBMCs) were isolated, and B cells were classified into five subsets using flow cytometry based on CD24 and CD38 expression. CD37 expression was evaluated, and functional differences between CD37+ and CD37- B cells were compared. Peripheral lymphocytes were stimulated with LPS to observe changes in CD37 expression. The expression of CD37 and related B cell subsets was also compared between pSS patients and healthy controls, followed by ROC curve analysis.</div></div><div><h3>Results</h3><div>CD37 was highly expressed in early-stage B cells, with a significant decrease in effector cells. CD37+ <em>B</em> cells exhibited higher proportions of CD40+, HLA-DR+, and IL-10+ cells, indicating enhanced antigen-presenting and regulatory capabilities. Post-LPS stimulation, CD37 expression significantly declined in pSS patients compared to healthy controls, suggesting increased sensitivity to differentiation into plasma cells. Additionally, CD37-related B cell subsets in pSS patients showed strong correlations with autoantibodies and immunological markers. ROC analysis revealed substantial areas under the curve, confirming the diagnostic potential of these subsets.</div></div><div><h3>Conclusion</h3><div>The expression of CD37 in B cell subsets is variable, indicating a potential regulatory role in B cell function and offering auxiliary diagnostic value in pSS.</div></div>","PeriodicalId":13413,"journal":{"name":"Immunology letters","volume":"276 ","pages":"Article 107054"},"PeriodicalIF":3.3000,"publicationDate":"2025-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Immunology letters","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0165247825000872","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objective

This study aims to analyse the expression of CD37 in different B cell subsets from human peripheral blood, exploring changes in CD37 expression in B cells of patients with primary Sjögren's syndrome (pSS) and assessing their clinical relevance.

Methods

A total of 32 pSS patients and age- and sex-matched healthy controls were included. Peripheral blood mononuclear cells (PBMCs) were isolated, and B cells were classified into five subsets using flow cytometry based on CD24 and CD38 expression. CD37 expression was evaluated, and functional differences between CD37+ and CD37- B cells were compared. Peripheral lymphocytes were stimulated with LPS to observe changes in CD37 expression. The expression of CD37 and related B cell subsets was also compared between pSS patients and healthy controls, followed by ROC curve analysis.

Results

CD37 was highly expressed in early-stage B cells, with a significant decrease in effector cells. CD37+ B cells exhibited higher proportions of CD40+, HLA-DR+, and IL-10+ cells, indicating enhanced antigen-presenting and regulatory capabilities. Post-LPS stimulation, CD37 expression significantly declined in pSS patients compared to healthy controls, suggesting increased sensitivity to differentiation into plasma cells. Additionally, CD37-related B cell subsets in pSS patients showed strong correlations with autoantibodies and immunological markers. ROC analysis revealed substantial areas under the curve, confirming the diagnostic potential of these subsets.

Conclusion

The expression of CD37 in B cell subsets is variable, indicating a potential regulatory role in B cell function and offering auxiliary diagnostic value in pSS.

Abstract Image

查看原文本刊更多论文

刺激后B细胞亚群CD37表达降低及其与原发性Sjögren综合征的临床相关性

目的：本研究旨在分析人外周血不同B细胞亚群中CD37的表达，探讨原发性Sjögren’s综合征（pSS）患者B细胞中CD37表达的变化并评估其临床意义。方法：共纳入32例pSS患者和21例年龄和性别匹配的健康对照。分离外周血单个核细胞（PBMCs），利用流式细胞术根据CD24和CD38的表达将B细胞分为5个亚群。检测CD37表达，比较CD37+和CD37- B细胞的功能差异。LPS刺激外周血淋巴细胞观察CD37表达变化。比较pSS患者与健康对照组CD37及相关B细胞亚群的表达，并进行ROC曲线分析。结果：CD37在早期B细胞中高表达，在效应细胞中低表达。CD37+ B细胞中CD40+、HLA-DR+和IL-10+细胞的比例更高，表明抗原提呈和调节能力增强。lps刺激后，与健康对照组相比，pSS患者的CD37表达显著下降，表明分化为浆细胞的敏感性增加。此外，pSS患者的cd37相关B细胞亚群与自身抗体和免疫标志物有很强的相关性。ROC分析显示曲线下有大量区域，证实了这些子集的诊断潜力。结论：CD37在B细胞亚群中的表达是可变的，提示其在B细胞功能中具有潜在的调节作用，对pSS具有辅助诊断价值。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Immunology letters 医学-免疫学

CiteScore

7.60

自引率

0.00%

发文量

审稿时长

44 days

期刊介绍： Immunology Letters provides a vehicle for the speedy publication of experimental papers, (mini)Reviews and Letters to the Editor addressing all aspects of molecular and cellular immunology. The essential criteria for publication will be clarity, experimental soundness and novelty. Results contradictory to current accepted thinking or ideas divergent from actual dogmas will be considered for publication provided that they are based on solid experimental findings. Preference will be given to papers of immediate importance to other investigators, either by their experimental data, new ideas or new methodology. Scientific correspondence to the Editor-in-Chief related to the published papers may also be accepted provided that they are short and scientifically relevant to the papers mentioned, in order to provide a continuing forum for discussion.